Compare VEON & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | VCYT |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.1B |
| IPO Year | 2010 | 2013 |
| Metric | VEON | VCYT |
|---|---|---|
| Price | $56.31 | $45.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $73.40 | $44.00 |
| AVG Volume (30 Days) | 107.2K | ★ 955.6K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 164.52 |
| EPS | N/A | ★ 0.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | $13.76 |
| Revenue Next Year | $1.60 | $12.35 |
| P/E Ratio | ★ $6.15 | $129.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.55 | $22.61 |
| 52 Week High | $64.00 | $50.71 |
| Indicator | VEON | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 63.01 | 74.03 |
| Support Level | $51.66 | $40.27 |
| Resistance Level | $63.38 | $45.64 |
| Average True Range (ATR) | 2.14 | 2.32 |
| MACD | 0.60 | 0.72 |
| Stochastic Oscillator | 92.37 | 93.36 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).